The share price of digital medical platforms in the United States has soared. Will the new acquisition unlock the health investment outlet?

① The share price of U.S. health and wellness platform HIMS rose nearly 25% on Wednesday, reaching a high of US$72.98, a record high.
②HIMS announced the acquisition of Trybe Labs, a home self-service laboratory testing agency, to support customers to draw blood at home for testing.

Cailian News, February 20 (Editor Zhao Hao)On Wednesday (February 19), U.S. health and wellness platform Hims Hers Health (ticker code: HIMS) once rose nearly 25%, with its stock price reaching a record high of US$72.98.

Daily chart of Hims Hers Health stock price

This month, HIMS has risen by more than 87%. The stock has risen nearly 190% year-to-date, exceeding the 171% increase for the whole year of 2024.

In the news, HIMS announced that it has acquired Sigmund NJ LLC, a “home self-service” laboratory testing firm (sold under the name “Trybe Labs”). The deal allows HIMS to support customers to draw blood at home for more comprehensive full-body testing.

It is understood that Trybe Labs ‘flagship product is a blood sampling device (pictured). Customers can collect their own blood through the device at home, which is more convenient than blood collection at fingertips and will not cause pain.

Source: Trybe Labs official website

Using collected blood, Trybe Labs can help customers measure information on hormone levels, heart risk, stress indicators, cholesterol, liver function, thyroid function and prostate health, which HIMS can use to determine the personalized treatment plan that best suits customers.

HIMS currently covers areas such as hair health, mental health, sexual health, weight management, etc. The company also launched a compound version of semigroutide in May last year, which is relatively affordable compared with Novo Nordisk’s drugs and reduces consumer financial burden.

HIMS said the acquisition of Trybe Labs will allow customers to take control of their health through deeper insights and give medical providers access to a wide range of data and biomarkers to help identify disease risks before they develop, making more precise clinical decisions.